Literature DB >> 25879354

Feasibility study of robotic hypofractionated lung radiotherapy by individualized internal target volume and XSight Spine Tracking: a preliminary dosimetric evaluation.

Mark K H Chan1, Dora L W Kwong, Venus W Y Lee, Ronnie W K Leung, Mathew Y P Wong, Oliver Blanck.   

Abstract

AIM: To investigate the dosimetric impacts of lung tumor motion in robotic hypofractionated radiotherapy for lung cancers delivered through continuous tracking of the vertebrae by the XSight Spine Tracking (XST) mode of the CyberKnife.
MATERIALS AND METHODS: Four-dimensional computed tomography (4DCT) scans of a dynamic thorax phantom were acquired. Three motion patterns (one-dimensional and three-dimensional) of different range were investigated. Monte Carlo dose distributions were generated with 4DCT-derived internal target volume (ITV) with a treatment-specific setup margin for 12.6 Gy/3 fractions. Six-dimensional error correction was performed by kV stereoscopic imaging of the phantom's spine. Dosimetric effects of intrafractional tumor motion were assessed with Gafchromic films (Ashland Inc, Wayne, NJ, USA) according to 1) the percent measurement dose points having doses above the prescribed (P (> Dpres)), mean (P (> Dm)), and minimum (P (> Dmin)) ITV doses, and 2) the coefficient of variation (CV).
RESULTS: All plans attained the prescription dose after three fractions despite marked temporal dose variations. The value of P (> Dpres) was 100% after three fractions for all plans, but could be smaller (~96%) for one fraction. The values of P (> Dmin) and P (> Dm) varied drastically interfractionally (25%-2%), and could be close to 0% after three fractions. The average CV ranged from 2.8% to 7.0%. Correlations with collimator size were significant for P (> Dmin) and P (> Dm) (P < 0.05) but not P (> Dpres) (P > 0.05).
CONCLUSIONS: Treating lung tumors with CyberKnife through continuous tracking of the vertebrae should not be attempted without effective means to reduce the amplitude and variability of target motion because temporal dose variations owing to the intrafractional target motion can be significant.

Entities:  

Mesh:

Year:  2015        PMID: 25879354     DOI: 10.4103/0973-1482.138220

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  5 in total

1.  Cyberknife® stereotactic radiation therapy for stage I lung cancer and pulmonary metastases: evaluation of local control at 24 months.

Authors:  Myriam Khadige; Julia Salleron; Vincent Marchesi; Guillaume Oldrini; Didier Peiffert; Véronique Beckendorf
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Dosimetric Effect of Intrafraction Tumor Motion in Lung Stereotactic Body Radiotherapy Using CyberKnife Static Tracking System.

Authors:  Yu Chang; Hong-Yuan Liu; Zhi-Wen Liang; Xin Nie; Jing Yang; Gang Liu; Qin Li; Zhi-Yong Yang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

3.  Integrating CVH and LVH metrics into an optimization strategy for the selection of Iris collimator for Cyberknife Xsight lung tracking treatment.

Authors:  Feng Xiao; Yu Chang; Sheng Zhang; Zhiyong Yang
Journal:  J Appl Clin Med Phys       Date:  2021-01-11       Impact factor: 2.102

4.  Comparison of Two Cyberknife Planning Approaches for Multiple Brain Metastases.

Authors:  Tianlong Ji; Yaowen Song; Xinyu Zhao; Yuzi Wang; Guang Li
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

5.  Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors.

Authors:  Rene Baumann; Mark K H Chan; Florian Pyschny; Susanne Stera; Bettina Malzkuhn; Stefan Wurster; Stefan Huttenlocher; Marcella Szücs; Detlef Imhoff; Christian Keller; Panagiotis Balermpas; Dirk Rades; Claus Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck
Journal:  Front Oncol       Date:  2018-05-17       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.